My expectation is that it will be a slow burn without significant price sensitive news for 3-6 months. the catalysts may be another meeting with the FDA/EMA which is unscheduled to investors knowledge (ie. no date known). The pharmacokinetics study and phase 3 designs more likely 1H CY 2021. With such a tightly held register I would expect that if positive release from any of the above then it will re-rate sharply IMO. Circa opthea though maybe not to same 400% extent. My thoughts only.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
9.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.763M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5 | 9.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 9.7¢ | 9000 | 1 |
View Market Depth
| Last trade - 16.21pm 15/07/2025 (20 minute delay) ? |
| IXC (ASX) Chart |
Day chart unavailable